08:04 AM EDT, 09/12/2025 (MT Newswires) -- Polyrizon ( PLRZ ) shares were up more than 42% in Friday's premarket activity after the company said its PL-14 allergy blocker achieved over 60% deposition in the nasal vestibule, the first region exposed to airborne allergens, in a preclinical study.

The study, which evaluated the spray deposition profile of PL-14, reinforced the product's potential as a barrier-forming treatment for allergic rhinitis, the company said.

The targeted delivery can effectively block allergen contact with the nasal mucosa, capturing and containing environmental allergens before they trigger an immune response, the company said.